.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Dow
Deloitte
Novartis
Citi
Mallinckrodt
Merck
Harvard Business School
Johnson and Johnson

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 085583

« Back to Dashboard
NDA 085583 describes QUINIDINE SULFATE, which is a drug marketed by Lilly, Purepac Pharm, Contract Pharmacal, Vangard, Dava Pharms Inc, Sandoz, Elkins Sinn, Perrigo, Pharmavite, Sun Pharm Inds, Cycle Pharms Ltd, Usl Pharma, Everylife, Watson Labs, Lannett, Whiteworth Town Plsn, G And W Labs Inc, Impax Labs, Ivax Sub Teva Pharms, Hikma Pharms, Vintage Pharms, Scherer Labs, Superpharm, King Pharms, Kv Pharm, Lederle, Barr, Warner Chilcott, Halsey, and Valeant Pharm Intl, and is included in forty NDAs. It is available from three suppliers. Additional details are available on the QUINIDINE SULFATE profile page.

The generic ingredient in QUINIDINE SULFATE is quinidine sulfate. There are twenty-six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the quinidine sulfate profile page.

Summary for NDA: 085583

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 085583

Mechanism of ActionCytochrome P450 2D6 Inhibitors

Suppliers and Packaging for NDA: 085583

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
QUINIDINE SULFATE
quinidine sulfate
 TABLET;ORAL 085583 ANDA Watson Laboratories, Inc. 0591-5454 0591-5454-01 100 TABLET in 1 BOTTLE, PLASTIC (0591-5454-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength300MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Colorcon
Federal Trade Commission
US Department of Justice
Healthtrust
QuintilesIMS
Fuji
McKesson
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot